Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis

Clinical Immunology

Volumn 134, Issue 3, 2010, Pages 331-339

  Parietti, Véronique ^a   Chifflot, Hélène ^a,b   Sibilia, Jean ^b   Muller, Sylviane ^a   Monneaux, Fanny ^a  

^a CNRS   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Autoimmunity; iNKT cells; Rheumatoid arthritis; Rituximab

Indexed keywords

ADALIMUMAB; CD1D ANTIGEN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGULATORY MECHANISM; REMISSION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FLOW CYTOMETRY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; SEX FACTORS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 76049105418     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.11.007     Document Type: Article

References (46)

1. Bendelac A., Rivera M.N., Park S.H., and Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15 (1997) 535-562
2. Morita M., Motoki K., Akimoto K., Natori T., Sakai T., Sawa E., Yamaji K., Koezuka Y., Kobayashi E., and Fukushima H. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J. Med. Chem. 38 (1995) 2176-2187
3. Kobayashi E., Motoki K., Uchida T., Fukushima H., and Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7 (1995) 529-534
4. Chen H., and Paul W.E. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J. Immunol. 159 (1997) 2240-2249
5. Wilson S.B., Kent S.C., Patton K.T., Orban T., Jackson R.A., Exley M., Porcelli S., Schatz D.A., Atkinson M.A., Balk S.P., Strominger J.L., and Hafler D.A. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391 (1998) 177-181
6. Sumida T., Sakamoto A., Murata H., Makino Y., Takahashi H., Yoshid S., Nishioka K., Iwamoto I., and Taniguchi M. Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J. Exp. Med. 182 (1995) 1163-1168
7. Illés Z., Kondo T., Newcombe J., Oka N., Tabira T., and Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164 (2000) 4375-4381
8. Singh A.K., Wilson M.T., Hong S., Olivares-Villagómez D., Du C., Stanic A.K., Joyce S., Sriram S., Koezuka Y., and Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194 (2001) 1801-1811
9. Furlan R., Bergami A., Cantarella D., Brambilla E., Taniguchi M., Dellabona P., Casorati G., and Martino G. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur. J. Immunol. 33 (2003) 1830-1838
10. Hammond K.J., Poulton L.D., Palmisano L.J., Silveira P.A., Godfrey D.I., and Baxter A.G. alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med 187 (1998) 1047-1056
11. Lehuen A., Lantz O., Beaudoin L., Laloux V., Carnaud C., Bendelac A., Bach J.F., and Monteiro R.C. Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188 (1998) 1831-1839
12. Saubermann L.J., Beck P., De Jong Y.P., Pitman R.S., Ryan M.S., Kim H.S., Exley M., Snapper S., Balk S.P., Hagen S.J., Kanauchi O., Motoki K., Sakai T., Terhorst C., Koezuka Y., Podolsky D.K., and Blumberg R.S. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 119 (2000) 119-128
13. Yanagihara Y., Shiozawa K., Takai M., Kyogoku M., and Shiozawa S. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 118 (1999) 131-136
14. van der Vliet H.J., von Blomberg B.M., Nishi N., Reijm M., Voskuyl A.E., van Bodegraven A.A., Polman C.H., Rustemeyer T., Lips P., van den Eertwegh A.J., Giaccone G., Scheper R.J., and Pinedo H.M. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100 (2001) 144-148
15. Kojo S., Adachi Y., Keino H., Taniguchi M., and Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 44 (2001) 1127-1138
16. Tao D., Shangwu L., Qun W., Yan L., Wei J., Junyan L., Feili G., Boquan J., and Jinquan T. CD226 expression deficiency causes high sensitivity to apoptosis in NK T cells from patients with systemic lupus erythematosus. J. Immunol. 174 (2005) 1281-1290
17. Green M.R., Kennell A.S., Larche M.J., Seifert M.H., Isenberg D.A., and Salaman M.R. Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production. Arthritis Rheum. 56 (2007) 303-310
18. Wither J., Cai Y.C., Lim S., McKenzie T., Roslin N., Claudio J.O., Cooper G.S., Hudson T.J., Paterson A.D., Greenwood C.M.T., Gladman D., Pope J., Pineau C.A., Smith C.D., Hanly J.G., Peschken C., Boire G., and Fortin P.R. Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity. Arthritis Res. Ther. 10 (2008) R108
19. Lanier L.L., Chang C., and Phillips J.H. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J. Immunol. 153 (1994) 2417-2428
20. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: facts, functions and fallacies. Immunol. Today 21 (2000) 573-583
21. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
22. Lee P.T., Benlagha K., Teyton L., and Bendelac A. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195 (2002) 637-641
23. Gumpez J.E., Miyake S., Yamamura T., and Brenner M.B. Functional distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195 (2002) 625-636
24. Montoya C.J., Pollard D., Martinson J., Kumari K., Wasserfall C., Mulder C.B., Rugeles M.T., Atkinson M.A., Landay A.L., and Wilson S.B. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122 (2007) 1-14
25. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., and Luthra H.S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 (1988) 315-324
26. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., and Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25 (1982) 1271-1277
27. Prevoo M.L., van 't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., and van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38 (1995) 44-48
28. van Gestel A.M., Anderson J.J., van Riel P.L., Boers M., Haagsma C.J., Rich B., Wells G., Lange M.L., and Felson D.T. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J. Rheumatol 26 (1999) 705-711
29. Johansso U., Macey M.G., Kenny D., Provan D., and Newland A.C. Alpha-galactosylceramide-driven expansion of human natural killer T cells is inhibited by prednisolone treatment. Br. J. Haematol. 125 (2004) 400-444
30. Fuji S., Shimizu K., Kronenberg M., and Steinman R.M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3 (2002) 867-874
31. Smyth M.J., and Godfrey D.I. NKT cells and tumor immunity-a double-edged sword. Nat. Immunol. 1 (2000) 459-460
32. Linsen L., Thewissen M., Baete K., Somers V., Geusens P., Raus J., and Stinissen P. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res. Ther. 7 (2005) R493-502
33. Shao H., Van Kaer L., Sun S.L., Kaplan H.J., and Sun D. Infiltration of the inflamed eye by NKT cells in a rat model of experimental autoimmune uveitis. J. Autoimmun. 21 (2003) 37-45
34. Suárez A., López P., Gómez J., and Gutiérrez C. Enrichment of CD4+ CD25 high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann. Rheum. Dis. 65 (2006) 1512-1517
35. Sfikakis P.P., Souliotis V.L., Fragiadaki K.G., Moutsopoulos H.M., Boletis J.N., and Theofilopoulos A.N. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123 (2007) 66-73
36. Vigna-Perez M., Hernández-Castro B., Paredes-Saharopulos O., Portales-Pérez D., Baranda L., Abud-Mendoza C., and González-Amaro R. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8 (2006) R83
37. Vallersko T., Gunnarsson I., Widhe M., Risselada A., Klareskog L., van Vollenhoven R., Malmström V., and Trollmo C. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. 122 (2007) 62-74
38. Reis E.A.G., Athanazio D.A., Lima I., Silva N.O., Andrade J.C.S., Jesus R.N., Barbosa L.M., Reis M.G., and Santiago M.B. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheum. Intern. 29 (2009) 469-475
39. Feuchtenberger M., Müller S., Roll P., Waschbisch A., Schäfer A., Kneitz C., Wiendl H., and Tony H.P. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheum. J. 2 (2008) 81-88
40. De Vita S., and Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun. Rev. 5 (2006) 443-448
41. Martin F., and Chan A.C. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20 (2004) 517-527
42. Silverman G.J., and Carson D.A. Roles of B cells in rheumatoid arthritis. Arthritis Res. Ther. 5 Suppl. 4 (2003) S1-S6
43. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., A Iniotaki, and H.M. Moutsopulos. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52 (2005) 501-513
44. Stasi R., Del Poeta G., Stipa E., Evangelista M.L., Trawinska M.M., Cooper N., and Amadori S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110 (2007) 2924-2930
45. van der Vliet H.J., von Blomberg B.M., Hazenberg M.D., Nishi N., Otto S.A., van Benthem B.H., Prins M., Claessen F.A., van den Eertwegh A.J., Giaccone G., Miedema F., Scheper R.J., and Pinedo H.M. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J. Immunol. 168 (2002) 1490-1495
46. Suda T., Takahashi T., Golstein P., and Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75 (1993) 1169-1178